The National Cancer Institute (NCI) is offering a grant through its new Cancer Adoptive Cellular Therapy (Can-ACT) Network initiative. This grant is for accelerating the development and clinical testing of innovative cell therapy strategies, particularly for pediatric and adult solid tumors. The NCI aims to stimulate early-phase adoptive cellular therapy clinical trials by supporting multi-investigator teams. Emphasis is placed on collaborative approaches to preclinical and translational studies, enabling the swift advancement of novel cell therapy products from research into clinical application. This initiative seeks to foster a network of experts dedicated to bringing cutting-edge cellular therapies to patients, enhancing treatment options for challenging cancers.
Opportunity ID: 343219
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-22-029 |
| Funding Opportunity Title: | Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 24, 2022 |
| Last Updated Date: | Aug 24, 2022 |
| Original Closing Date for Applications: | Jun 30, 2023 |
| Current Closing Date for Applications: | Jun 30, 2023 |
| Archive Date: | Aug 05, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Special district governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-029.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00276545 | Sep 28, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278459 | Nov 15, 2022 | Jun 30, 2023 | View |
Package 1
Mandatory forms
343219 RR_SF424_5_0-5.0.pdf
343219 PHS398_CoverPageSupplement_5_0-5.0.pdf
343219 RR_OtherProjectInfo_1_4-1.4.pdf
343219 PerformanceSite_4_0-4.0.pdf
343219 RR_KeyPersonExpanded_4_0-4.0.pdf
343219 RR_Budget_3_0-3.0.pdf
343219 PHS398_ResearchPlan_4_0-4.0.pdf
343219 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343219 RR_SubawardBudget30_3_0-3.0.pdf
343219 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
343219 RR_SF424_5_0-5.0.pdf
343219 PHS398_CoverPageSupplement_5_0-5.0.pdf
343219 RR_OtherProjectInfo_1_4-1.4.pdf
343219 PerformanceSite_4_0-4.0.pdf
343219 RR_KeyPersonExpanded_4_0-4.0.pdf
343219 RR_Budget_3_0-3.0.pdf
343219 PHS398_ResearchPlan_5_0-5.0.pdf
343219 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343219 RR_SubawardBudget30_3_0-3.0.pdf
343219 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
